• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

新型乙肝抗病毒药物 E-CFCP 对肾脏有机酸转运体的影响。

Effects of a novel hepatitis B anti-viral drug E-CFCP in renal organic acid transporters.

机构信息

Department of Pharmacology, Chiba University Graduate School of Medicine, 1-8-1 Inohana, Chuo, Chiba 260-8670, Japan.

Department of Refractory Viral Infections, National Center for Global Health & Medicine Research Institute, Tokyo, Japan.

出版信息

J Pharmacol Sci. 2022 Dec;150(4):201-203. doi: 10.1016/j.jphs.2022.09.002. Epub 2022 Sep 16.

DOI:10.1016/j.jphs.2022.09.002
PMID:36344041
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10722831/
Abstract

Currently, the emergence of drug resistance is an important issue in the treatment of hepatitis B virus (HBV). Recently, our collaborating group developed a novel long-acting anti-HBV drug, E-CFCP. However, until this study, the effects of E-CFCP in the kidney have remained unclarified. Using cell viability and uptake assays, we examined the effects of E-CFCP on the function of renal organic anion transporters (OATs). No cytotoxicity was shown related to the E-CFCP in the renal OATs in either assay. Thus, this study suggested that E-CFCP may be a novel, excellent candidate drug for the treatment of drug-resistant HBV.

摘要

目前，耐药性的出现是乙型肝炎病毒 (HBV) 治疗中的一个重要问题。最近，我们的合作小组开发了一种新型长效抗乙型肝炎病毒药物 E-CFCP。然而，直到这项研究，E-CFCP 在肾脏中的作用仍不清楚。通过细胞活力和摄取试验，我们研究了 E-CFCP 对肾脏有机阴离子转运体 (OATs) 功能的影响。在两种试验中，E-CFCP 对肾脏 OATs 的功能均未显示出与细胞毒性相关的作用。因此，本研究表明，E-CFCP 可能是一种新型的、优秀的治疗耐药性乙型肝炎病毒的候选药物。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e9a/10722831/3812f46056ea/nihms-1941298-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e9a/10722831/21d941a771ca/nihms-1941298-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e9a/10722831/bd4b1f84e56f/nihms-1941298-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e9a/10722831/3812f46056ea/nihms-1941298-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e9a/10722831/21d941a771ca/nihms-1941298-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e9a/10722831/bd4b1f84e56f/nihms-1941298-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e9a/10722831/3812f46056ea/nihms-1941298-f0003.jpg

相似文献

1
Effects of a novel hepatitis B anti-viral drug E-CFCP in renal organic acid transporters.新型乙肝抗病毒药物 E-CFCP 对肾脏有机酸转运体的影响。
J Pharmacol Sci. 2022 Dec;150(4):201-203. doi: 10.1016/j.jphs.2022.09.002. Epub 2022 Sep 16.
2
Identification of a novel long-acting 4'-modified nucleoside reverse transcriptase inhibitor against HBV.鉴定一种新型长效 4’-修饰核苷类逆转录酶抑制剂抗乙肝病毒。
J Hepatol. 2021 May;74(5):1075-1086. doi: 10.1016/j.jhep.2020.12.006. Epub 2020 Dec 15.
3
Deviated binding of anti-HBV nucleoside analog E-CFCP-TP to the reverse transcriptase active site attenuates the effect of drug-resistant mutations.抗乙肝病毒核苷类似物 E-CFCP-TP 与逆转录酶活性部位的偏离结合削弱了耐药突变的作用。
Sci Rep. 2024 Jul 8;14(1):15742. doi: 10.1038/s41598-024-66505-z.
4
A novel anti-HBV agent, E-CFCP, restores Hepatitis B virus (HBV)-induced senescence-associated cellular marker perturbation in human hepatocytes.新型抗乙肝病毒药物 E-CFCP 恢复人肝细胞中乙型肝炎病毒（HBV）诱导的衰老相关细胞标志物紊乱。
Virus Res. 2023 May;329:199094. doi: 10.1016/j.virusres.2023.199094. Epub 2023 Mar 23.
5
CMCdG, a Novel Nucleoside Analog with Favorable Safety Features, Exerts Potent Activity against Wild-Type and Entecavir-Resistant Hepatitis B Virus.CMCdG，一种具有良好安全性特征的新型核苷类似物，对野生型和恩替卡韦耐药的乙型肝炎病毒具有强大的活性。
Antimicrob Agents Chemother. 2019 Mar 27;63(4). doi: 10.1128/AAC.02143-18. Print 2019 Apr.
6
Interactions with selected drug renal transporters and transporter-mediated cytotoxicity in antiviral agents from the group of acyclic nucleoside phosphonates.无环核苷膦酸类抗病毒药物与选定的药物肾转运体的相互作用及转运体介导的细胞毒性。
Toxicology. 2013 Sep 15;311(3):135-46. doi: 10.1016/j.tox.2013.07.004. Epub 2013 Jul 13.
7
In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir.拉米夫定耐药乙型肝炎病毒对阿德福韦和替诺福韦的体外敏感性
Antivir Ther. 2004 Jun;9(3):353-63.
8
Evolution of hepatitis B viral load and viral genome sequence during adefovir dipivoxil therapy.阿德福韦酯治疗期间乙肝病毒载量及病毒基因组序列的演变
J Viral Hepat. 2004 Jan;11(1):74-83. doi: 10.1046/j.1365-2893.2003.00471.x.
9
Lamivudine and Famciclovir resistant hepatitis B virus associated with fatal hepatic failure.与致命性肝衰竭相关的拉米夫定和泛昔洛韦耐药乙型肝炎病毒
J Clin Virol. 2003 May;27(1):111-6. doi: 10.1016/s1386-6532(02)00167-1.
10
A Novel Tricyclic Polyketide, Vanitaracin A, Specifically Inhibits the Entry of Hepatitis B and D Viruses by Targeting Sodium Taurocholate Cotransporting Polypeptide.一种新型三环聚酮化合物瓦尼他菌素A通过靶向牛磺胆酸钠共转运多肽特异性抑制乙型和丁型肝炎病毒的进入。
J Virol. 2015 Dec;89(23):11945-53. doi: 10.1128/JVI.01855-15. Epub 2015 Sep 16.

本文引用的文献

1
Effects of islatravir (4'-ethynyl-2-fluoro-2'-deoxyadenosine or EFdA) on renal tubular cells and islatravir's interactions with organic anion transporters.依发韦仑（4'-乙炔基-2-氟-2'-脱氧腺苷或 EFdA）对肾小管细胞的影响及其与有机阴离子转运体的相互作用。
J Pharmacol Sci. 2021 Jun;146(2):82-87. doi: 10.1016/j.jphs.2021.03.004. Epub 2021 Mar 19.
2
Identification of a novel long-acting 4'-modified nucleoside reverse transcriptase inhibitor against HBV.鉴定一种新型长效 4’-修饰核苷类逆转录酶抑制剂抗乙肝病毒。
J Hepatol. 2021 May;74(5):1075-1086. doi: 10.1016/j.jhep.2020.12.006. Epub 2020 Dec 15.
3
Japan Society of Hepatology Guidelines for the Management of Hepatitis B Virus Infection: 2019 update.
日本肝脏学会乙型肝炎病毒感染管理指南：2019年更新版
Hepatol Res. 2020 Aug;50(8):892-923. doi: 10.1111/hepr.13504. Epub 2020 Jul 15.
4
Tenofovir alafenamide nephrotoxicity in an HIV-positive patient: A case report.一名HIV阳性患者的替诺福韦艾拉酚胺肾毒性：病例报告。
Medicine (Baltimore). 2017 Sep;96(36):e8046. doi: 10.1097/MD.0000000000008046.
5
Organic cation transporter OCTs (SLC22) and MATEs (SLC47) in the human kidney.人肾脏中的有机阳离子转运体 OCTs（SLC22）和 MATEs（SLC47）。
AAPS J. 2013 Apr;15(2):581-8. doi: 10.1208/s12248-013-9465-7. Epub 2013 Feb 22.
6
Urate transport via human PAH transporter hOAT1 and its gene structure.尿酸盐通过人类PAH转运体hOAT1的转运及其基因结构。
Kidney Int. 2003 Jan;63(1):143-55. doi: 10.1046/j.1523-1755.2003.00710.x.
7
Characterization of methotrexate transport and its drug interactions with human organic anion transporters.甲氨蝶呤转运及其与人类有机阴离子转运体的药物相互作用的表征
J Pharmacol Exp Ther. 2002 Aug;302(2):666-71. doi: 10.1124/jpet.102.034330.
8
Role of organic anion transporter 1 (OAT1) in cephaloridine (CER)-induced nephrotoxicity.有机阴离子转运体1（OAT1）在头孢菌素（CER）诱导的肾毒性中的作用。
Kidney Int. 1999 Dec;56(6):2128-36. doi: 10.1046/j.1523-1755.1999.00789.x.
9
Cisplatin-induced toxicity in immortalized renal cell lines established from transgenic mice harboring temperature sensitive SV40 large T-antigen gene.顺铂对携带温度敏感型SV40大T抗原基因的转基因小鼠所建立的永生化肾细胞系的毒性作用。
Arch Toxicol. 1996;70(5):284-92. doi: 10.1007/s002040050275.